Partnership in pursuit of new antibiotics...A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel … more ➔
Drug puts CAR T activity on hold German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact. more ➔
License deal in oncolytic virotherapiesOncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer … more ➔
Boehringer Ingelheim and Yuhan Corp. in US...Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay … more ➔
Smart bra set to detect breast cancerA French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography. more ➔
GARDP wants five AMR breakers by 2025GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025. more ➔
Sanifit raise €72.2m to push SNF472 deve...Sanifit has bagged €72.2m in Spains largest private biotech fundraise. more ➔
Genfit in $228m deal with Terns Pharmaceut...Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.   … more ➔
Vesalius Biocapital III Fund closes at €...Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m. more ➔
Erytech Pharma SA bags US$57m from SQZ Bio...Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies. more ➔
